UNITED STATES

  SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 1, 2016

 

PHARMATHENE, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware 001-32587 20-2726770
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

  

One Park Place, Suite 450
Annapolis, Maryland 		  21401
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (410) 269-2600

 

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 1, 2016, the board of directors of PharmAthene, Inc. (the "Company") granted John M. Gill, the Company's chief executive officer, a stock option to purchase 100,000 shares of the Company’s common stock at an exercise price of $2.20, the closing price of the Company’s common stock as reported on the NYSE:MKT on June 1, 2016. The stock option vests over a 3 year period (subject to acceleration upon the occurrence of certain events) with 25% vesting immediately and 25% vesting on each of the first, second and third anniversaries of the grant date and will expire on May 31, 2026. In addition, on June 1, 2016, the Company agreed to pay Mr. Gill a $25,000 discretionary cash bonus.

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the annual meeting of stockholders (the “Annual Meeting”) of the Company held on June 1, 2016, the holders of the Company’s common stock voted to elect each of the following directors to serve until the next annual meeting and until his successor is duly elected and qualified:

 

Director   Votes For   Votes Withheld   Broker Non-Votes
John M. Gill   30,156,342   949,024   20,953,969
Eric I. Richman   30,155,923   949,443   20,953,969
Jeffrey W. Runge, M.D.   30,126,342   979,024   20,953,969
Mitchel B. Sayare, Ph.D.   30,126,023   979,343   20,953,969
Derace L. Schaffer, M.D.   30,126,442   978,924   20,953,969
Steven St. Peter, M.D.   30,155,923   949,443   20,953,969

 

At the Annual Meeting, the Company’s stockholders also voted on the following proposals:

 

Proposal   For   Against   Abstain   Broker Non-Votes
To ratify the Company's Tax Benefit Preservation Plan designed to protect the tax benefit of the Company's net operating loss carryforwards.   30,806,349   255,829   43,188   20,953,969
To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015   51,666,301   374,843   18,191   N/A

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PHARMATHENE, INC.  

   
     
Date:  June 7, 2016 By:   /s/ Philip MacNeill
   

Philip MacNeill

Vice President, Chief Financial Officer, Treasurer and Secretary

 

 

 

 

 

Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pharmathene, (delisted) Charts.
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pharmathene, (delisted) Charts.